731 related articles for article (PubMed ID: 17922852)
1. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
3. Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array.
Jin X; Wu XX; Jin C; Inui M; Sugimoto M; Kakehi Y
Anticancer Drugs; 2012 Apr; 23(4):445-54. PubMed ID: 22205156
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
[TBL] [Abstract][Full Text] [Related]
5. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
6. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
Zhang L; Zhang X; Barrisford GW; Olumi AF
Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
8. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
10. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
11. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
12. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
[TBL] [Abstract][Full Text] [Related]
14. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
[TBL] [Abstract][Full Text] [Related]
16. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
17. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
[TBL] [Abstract][Full Text] [Related]
19. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
